Philips to repurchase up to 6 million shares to cover long-term incentive plans
June 4, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million.
The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company's General Meeting of Shareholders on May 8, 2025. Philips expects to take delivery of the shares in 2027. Further details will be available via this link.
For further information, please contact:Michael FuchsPhilips Global External RelationsTel.: +31 6 1486 9261E-mail: michael.fuchs@philips.com
Dorin DanuPhilips Investor RelationsTel.: +31 20 59 77055E-mail: dorin.danu@philips.com
About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statementsThis release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
Plunging UK Retail Sales Deepen Concern About Broader Slowdown
A dramatic drop in UK retail sales is raising fresh questions about the sustainability of Britain's recent growth spurt and Prime Minister Keir Starmer's plans to use it to restore controversial benefit cuts. The volume of goods sold online and in shops dropped 2.7% in May, the Office for National Statistics said on Friday. Not only was that the sharpest decline since December 2023, it was enough to wipe out the combined gains over the previous four months of the year. Economists had expected retail sales to fall only 0.5% last month.
Yahoo
2 hours ago
- Yahoo
Protesters slam war profiteering, Israel at French air fair
Thousands marched on Saturday outside a French trade fair, calling for an end to war profiteering and Israel's offensive in Gaza in the latest demonstration to hit the event. The long-planned protest at the Paris Air Show outside the French capital also comes as Israel's war with Iran drags on into a ninth day, with Tehran threatening to hit back in force at Israel's offensive against its arch-rival. The presence of Israeli defence firms at the show has already become a bone of contention, with the French government on Monday sealing off the booths of five Israeli firms on the grounds that they were displaying offensive weapons that could be used in Gaza. "Their wars, their profits, our deaths, stop the genocide in Palestine," read the banner at the head of the march, which organisers claimed drew more than 4,000 protesters. "As we speak, people are dying and our governments are not doing anything to stop it," Nora, 29, told AFP at the protest. Draped in a Palestinian flag, the project leader in the pharmaceutical industry said that she felt "rage" at the footage coming out of Gaza, including that of "mothers kissing their dead children" in the besieged Palestinian territory. Police have arrested seven people aiming to disrupt the trade fair, the Paris public prosecutor office said, with officers discovering a helium canister and nearly 200 balloons during the searches. Six of the arrests were made on Friday and the other on Saturday, the prosecutor's office added. Drawing some 100,000 visitors a day, the Paris Air Show at the Le Bourget airfield, nine kilometres (five miles) to the north of the capital, is usually dominated by displays of the aerospace industry's latest cutting-edge planes. But Monday's shuttering of the stands of Israel Aerospace Industries (IAI), Rafael, UVision and Elbit, as well as Aeronautics, which make drones and guided bombs and missiles, sparked a row with Israel. Israel's President Isaac Herzog branded Paris's closure of the Israeli firms' booths "outrageous", comparing it to "creating an Israeli ghetto". It came days after Israel, claiming Iran was on the verge of obtaining a nuclear bomb, launched a surprise barrage on June 13 which killed top Iranian commanders and nuclear scientists. Tehran immediately hit back with a flurry of missiles, with the two countries trading wave after wave of devastating strikes since. lbx-mk/sha/sbk/
